Jean-Yves Douillard MD, PhD
Professor Emeritus, Medical Oncology, University of Nantes; Senior Advisor, Integrated Centers of Oncology (ICO), Nantes, FranceDr. Jean-Yves Douillard is a leading international expert in lung cancer and gastrointestinal oncology, and, over the course of a long career, he has held a number of leadership positions, including at the University of Nantes, where he was Professor in Medical Oncology, and at the Integrated Centers of Oncology (ICO) in Nantes, as Head of the Medical Oncology Department and later as Director of Clinical and Translational Research. He has also held senior ESMO positions, serving as Educational Committee Chair and as a member of the Executive Board.
Throughout his career, Dr. Douillard has led clinical trials in lung cancer and gastrointestinal tumors and has investigated targeted therapies, publishing his work in leading scientific journals. His clinical interests also include early drug development and translational research.
Currently, Dr. Doullard is serving as Senior Advisor in early clinical trial research at the Integrated Centers of Oncology.
Recent Contributions to PracticeUpdate:
- ESMO 2023: Recommendations From Dr. Jean-Yves Douillard for Lung Cancer
- Lazertinib vs Gefitinib Tyrosine Kinase Inhibitors for Treatment-Naïve EGFR-Mutated Advanced NSCLC
- 2022 Top Story in Oncology: Immunotherapy for the First-Line Treatment of Metastatic/Recurrent NSCLC
- Long-Term Survival Outcomes With Nivolumab Plus Ipilimumab vs Chemotherapy as First-Line Treatment for Metastatic NSCLC
- ESMO 2022: Recommendations From Dr. Jean-Yves Douillard for Non–Small Cell Lung Cancer
- Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA NSCLC
- ASCO 2022: Abstract Recommendations From Dr. Jean-Yves Douillard for Lung Cancer
- Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer
- Treatment Outcome of Atypical EGFR Mutations
- Five-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC